Hypothesis

Age‑related decline in CTP:phosphocholine cytidylyltransferase (CT alpha) activity specifically within astrocytes reduces local phosphatidylcholine (PC) synthesis at synaptic mitochondria, impairing mitochondrial membrane fluidity and vesicular acetylcholine (ACh) release. This astrocytes‑centric lipid defect precedes and amplifies global cholinergic loss seen in Alzheimer’s disease (AD), independent of circulating choline levels.

Mechanistic Rationale

• The Kennedy pathway supplies PC for both bulk membranes and specialized organelles such as mitochondria, where PC modulates cardiolipin composition and inner‑membrane curvature (see LPCAT1 studies)[4].
• Astrocytes supply neurons with lactate and regulate extracellular choline; they also possess a high capacity for de novo PC synthesis via CT alpha. A selective drop in astrocytic CT alpha would limit PC available for mitochondrial membranes that buffer calcium at presynaptic terminals.
• Impaired mitochondrial PC increases membrane rigidity, hindering the conformational changes of synaptotagmin and SNARE complexes needed for ACh vesicle fusion, thereby reducing ACh release despite normal choline acetyltransferase (ChAT) activity.
• Reduced ACh feeding back onto astrocytic nicotinic receptors diminishes calcium‑stimulated CT alpha expression, creating a vicious cycle that couples lipid deficit to cholinergic hypofunction.
• This model explains why dietary choline supplementation (which raises substrate) shows modest clinical benefit[6][7] while genetic or pharmacologic CT alpha enhancement could rescue synaptic function even when plasma choline remains low.

Predictions & Experimental Tests

1. Human imaging – PET ligands targeting CT alpha activity will show lower binding in astrocytic-rich regions (e.g., hippocampus, cortex) of mild cognitive impairment (MCI) patients correlating with reduced CSF ACh levels, but not with plasma choline.[1]
2. Astrocyte‑specific rescue – In APP/PS1 mice, viral overexpression of CT alpha in GFAP‑positive cells will restore mitochondrial PC (measured by mass spectrometry), normalize synaptic vesicle release probability (via electrophysiology), and improve memory performance without altering global choline levels.
3. Pharmacologic challenge – Acute inhibition of CT alpha with hemicholinium‑3 in wild‑type mice will cause a rapid decline in evoked hippocampal ACh release (microdialysis) despite adequate extracellular choline, mimicking the deficit seen in aged animals.
4. One‑carbon flux interaction – Elevating homocysteine via methionine‑rich diet will exacerbate the CT alpha‑deficit phenotype, linking impaired methylation capacity to reduced CT alpha expression (as observed in choline deficiency models)[5].

Potential Confounds & Controls

• Neuronal CT alpha changes – Use cell‑type‑specific promoters to isolate astrocytic effects; verify neuronal CT alpha remains unchanged via immunohistochemistry.
• Global lipid alterations – Measure total brain PC by lipidomics to ensure observed effects are localized to mitochondrial fractions.
• Off‑target drug effects – Employ multiple CT alpha inhibitors with distinct mechanisms and include vehicle controls.
• Reverse causality – Longitudinal PET‑MRI cohorts will test whether baseline CT alpha decline predicts future cholinergic loss, not vice‑versa.

This hypothesis is falsifiable: if astrocytic CT alpha activity remains stable across the aging spectrum or its manipulation fails to rescue mitochondrial PC and ACh release, the proposed mechanistic link between astrocytic lipid synthesis and synaptic cholinergic failure would be refuted.